Heartflow, Inc. (NASDAQ:HTFL) Receives Consensus Rating of “Moderate Buy” from Analysts

Heartflow, Inc. (NASDAQ:HTFL) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $37.6667.

A number of research analysts have recently issued reports on the company. Wells Fargo & Company decreased their target price on Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, March 19th. JPMorgan Chase & Co. decreased their target price on Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, March 19th. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Finally, Canaccord Genuity Group increased their target price on Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, March 19th.

Heartflow Price Performance

Shares of NASDAQ:HTFL opened at $31.34 on Wednesday. Heartflow has a 1 year low of $20.13 and a 1 year high of $41.22. The firm has a market capitalization of $2.69 billion and a price-to-earnings ratio of -15.75. The business’s 50 day moving average price is $24.87 and its 200-day moving average price is $29.47.

Insiders Place Their Bets

In related news, insider Campbell Rogers sold 65,153 shares of the stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $24.49, for a total value of $1,595,596.97. Following the completion of the transaction, the insider directly owned 76,034 shares of the company’s stock, valued at approximately $1,862,072.66. This represents a 46.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00. Following the completion of the transaction, the insider directly owned 10,448,158 shares of the company’s stock, valued at approximately $293,070,831.90. This represents a 16.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 2,279,027 shares of company stock worth $63,146,573.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HTFL. Caitong International Asset Management Co. Ltd purchased a new stake in Heartflow in the 4th quarter valued at $27,000. TFC Financial Management Inc. purchased a new stake in Heartflow in the 3rd quarter valued at $40,000. Russell Investments Group Ltd. purchased a new stake in Heartflow in the 4th quarter valued at $45,000. Legal & General Group Plc purchased a new stake in Heartflow in the 3rd quarter valued at $59,000. Finally, Strs Ohio purchased a new stake in Heartflow in the 4th quarter valued at $99,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.